TNF and metabolic dysfunction-associated steatotic liver disease: Furthermore, these interventions improved lipid profiles, as indicated by a reduction in triglycerides, and modulated inflammatory markers, including high-density lipoprotein and tumor necrosis factor alpha, in patients with MASLD, with potential implications for MASH [105].